Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Options

<< Previous

Bullboard Posts

Next >>

Comment by ScootsMcgootson Dec 10, 2023 1:41am

193 Views

Post# 35776690

RE:RE:RE:RE:Options

These guys know what's going on from the inside. MC/KL, that is. They've been selling a story of excitement and transformational year for ONC. If they don't buy their options then hold shares it'll be pretty clear what is really going on. They better become proud shareholders. I am watching very carefully as well.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders